PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study - Université de Bretagne Occidentale Access content directly
Journal Articles Lancet Oncology Year : 2019

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

Krimo Bouabdallah
  • Function : Author
Michel Meignan
  • Function : Author
  • PersonId : 855642

Abstract

Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated) improves progression-free survival in patients with advanced Hodgkin lymphoma compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), but is associated with increased risks of haematological toxicity, secondary myelodysplasia or leukaemia, and infertility. We investigated whether PET monitoring during treatment could allow dose de-escalation by switching regimen (BEACOPPescalated to ABVD) in early responders without loss of disease control compared with standard treatment without PET monitoring.
Programme Hospitalier de Recherche Clinique.

Dates and versions

hal-02263798 , version 1 (05-08-2019)

Identifiers

Cite

Rene-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Hervé Ghesquieres, et al.. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncology, 2019, 20 (2), pp.202-215. ⟨10.1016/S1470-2045(18)30784-8⟩. ⟨hal-02263798⟩
361 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More